CoChat

Effects of chronic administration of alogliptin on the development of diabetes and β ‐cell function in high fat diet/streptozotocin diabetic mice

Open access
Zhang, X., Wang, Z., Huang, Y., Wang, J. · 2011 · Diabetes, Obesity and Metabolism
Cited by 57

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aim: Alogliptin is a potent and highly selective dipeptidyl peptidase‐4 (DPP‐4) inhibitor. The aim of this study was to determine its effects on glucose control and pancreas islet function and to identify the underlying molecular mechanisms after chronic administration, in a non‐genetic mouse model of type 2 diabetes. Methods: Alogliptin (5, 15 and 45 mg/kg) was orally administered to high fat diet/streptozotocin (HFD/STZ) diabetic mice daily for 10 weeks. Postprandial and 6‐h fasting blood glucose levels, blood A1C level, oral glucose tolerance and pancreas insulin content were measured during or after the treatment period. Alogliptin plasma concentration was determined by an LC/MS/MS method. Islet morphology and architectural changes were evaluated with immunohistochemical analysis. Islet endocrine secretion ability was assessed by measuring insulin release from isolated islets which were challenged with 16 mM glucose and 30 mM potassium chloride, respectively. Gene expression profiles of the pancreas were analysed using the mouse diabetes RT 2 Profiler PCR array which contains 84 genes related to the onset, development and progression of diabetes. Results: Alogliptin showed dose‐dependent reduction of postprandial and fasting blood glucose levels and blood A1C levels. Glucose clearance ability and pancreas insulin content were both increased. Alogliptin significantly restored the β ‐cell mass and islet morphology, thus preserving islet function of insulin secretion. Expression of 10 genes including Ins1 was significantly changed in the pancreas of diabetic mice. Chronic alogliptin treatment completely or partially reversed the abnormalities in gene expression. Conclusions: Chronic treatment of alogliptin improved glucose control and facilitated restoration of islet architecture and function in HFD/STZ diabetic mice. The gene expression profiles suggest that the underlying molecular mechanisms of β ‐cell protection by alogliptin may involve alleviating endoplasmic reticulum burden and mitochondria oxidative stress, increasing β ‐cell differentiation and proliferation, enhancing islet architecture remodelling and preserving islet function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2010.01354.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 57

Metadata

Authors
Zhang, X., Wang, Z., Huang, Y., & Wang, J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-02-23
Volume
13
Issue
4
Pages
337-347
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2005404676
Cited by
57
References
9
FWCI
3.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of chronic administration of alogliptin on the development of diabetes and β ‐cell function in high fat diet/streptozotocin diabetic mice. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01354.x
The paper
Zhang, X., Wang, Z., Huang, Y., & Wang, J. (2011). Effects of chronic administration of alogliptin on the development of diabetes and β ‐cell function in high fat diet/streptozotocin diabetic mice. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01354.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.